The mediation role of allostatic load/chronic stress on the relationship between cancer survivorship and cardiovascular disease mortality.

Allostatic load Cancer Cancer survivor Cardiooncology Cardiovascular disease Chronic stress

Journal

American heart journal plus : cardiology research and practice
ISSN: 2666-6022
Titre abrégé: Am Heart J Plus
Pays: United States
ID NLM: 101779333

Informations de publication

Date de publication:
Sep 2024
Historique:
received: 31 12 2023
revised: 29 06 2024
accepted: 25 07 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 26 8 2024
Statut: epublish

Résumé

Cancer survivors face an elevated risk of cardiovascular disease (CVD) and cardiovascular disease mortality (CVDm) compared to the general population. Allostatic load (AL), a composite score reflecting cardiovascular, metabolic, and immune markers, assesses the cumulative impact of chronic stress and life events. Increased AL in cancer patients is linked to up to a 30 % higher CVD risk. We hypothesized that cancer diagnosis and therapy contribute to increased AL, mediating the association between cancer survivorship and CVDm. This retrospective cohort study analyzed National Health and Nutrition Examination Survey (NHANES) data linked with the National Death Index (NDI) from 1988 to 2019. Cancer survivorship (yes vs. no), AL, and CVDm were the exposure, mediator, and outcome variables, respectively. Mediation analyses adapted to survival outcomes were performed. Among 14,416 participants, cancer survivors <65 years-old exhibited a 41 % higher associated CVDm risk. High AL mediated 5.4 %, 8.9 %, and 3.6 % of the effect for all adults, 18-64 years, and ≥65 years, respectively. Black patients <65 years-old had an 84 % higher associated CVDm risk, with AL mediating 9.2 %, 5.8 %, and 12.6 % for all adults, 18-64 years, and ≥65 years, respectively. White patients showed a 20 % higher associated CVDm risk, with AL mediating 4.4 %, 2.8 %, and 5.7 % for all adults, 18-64 years, and ≥65 years, respectively. Increased CVDm risk among cancer survivors, particularly in Black individuals, is associated with higher AL mediation. These disparities may stem from social determinants of health.

Sections du résumé

Background UNASSIGNED
Cancer survivors face an elevated risk of cardiovascular disease (CVD) and cardiovascular disease mortality (CVDm) compared to the general population. Allostatic load (AL), a composite score reflecting cardiovascular, metabolic, and immune markers, assesses the cumulative impact of chronic stress and life events. Increased AL in cancer patients is linked to up to a 30 % higher CVD risk. We hypothesized that cancer diagnosis and therapy contribute to increased AL, mediating the association between cancer survivorship and CVDm.
Methods UNASSIGNED
This retrospective cohort study analyzed National Health and Nutrition Examination Survey (NHANES) data linked with the National Death Index (NDI) from 1988 to 2019. Cancer survivorship (yes vs. no), AL, and CVDm were the exposure, mediator, and outcome variables, respectively. Mediation analyses adapted to survival outcomes were performed.
Results UNASSIGNED
Among 14,416 participants, cancer survivors <65 years-old exhibited a 41 % higher associated CVDm risk. High AL mediated 5.4 %, 8.9 %, and 3.6 % of the effect for all adults, 18-64 years, and ≥65 years, respectively. Black patients <65 years-old had an 84 % higher associated CVDm risk, with AL mediating 9.2 %, 5.8 %, and 12.6 % for all adults, 18-64 years, and ≥65 years, respectively. White patients showed a 20 % higher associated CVDm risk, with AL mediating 4.4 %, 2.8 %, and 5.7 % for all adults, 18-64 years, and ≥65 years, respectively.
Conclusions UNASSIGNED
Increased CVDm risk among cancer survivors, particularly in Black individuals, is associated with higher AL mediation. These disparities may stem from social determinants of health.

Identifiants

pubmed: 39184148
doi: 10.1016/j.ahjo.2024.100429
pii: S2666-6022(24)00072-7
pmc: PMC11341928
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100429

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nickolas Stabellini (N)

Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Case Western Reserve University School of Medicine, Case Western Reserve University Cleveland, OH, United States.
Department of Hematology-Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, United States.
Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Darryl Nettles (D)

Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Cardio-Oncology Program, Department of Medicine, Cardiology Division, Medical College of Georgia at Augusta University, Augusta, GA, United States.

Priyanshu Nain (P)

Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Cardio-Oncology Program, Department of Medicine, Cardiology Division, Medical College of Georgia at Augusta University, Augusta, GA, United States.

Justin X Moore (JX)

Center for Health Equity Transformation, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, United States.
Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, United States.
Community Impact, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.

Neal L Weintraub (N)

Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States.

Sagar A Patel (SA)

Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.

Pedro Barata (P)

Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States.

Meng-Han Tsai (MH)

Georgia Prevention Institute, Augusta University, Augusta, GA 30912, United States.

Sadeer Al-Kindi (S)

Center for CV Computational & Precision Health (C3-PH), Houston Methodist Hospital, Houston, TX, United States.
Division of Cardiovascular Prevention & Wellness, Houston Methodist Hospital, Houston, TX, United States.

Avirup Guha (A)

Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Cardio-Oncology Program, Department of Medicine, Cardiology Division, Medical College of Georgia at Augusta University, Augusta, GA, United States.

Classifications MeSH